Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 22.79% is 19% above its 5-year average of 19.21%, near the high end of its 5-year range (-293.42%–48.52%).
22.40% above its 12-month average of 18.62%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 24.00%.
GROSS MARGIN
22.79%
GROSS MARGIN AVG TTM
18.62%
GROSS MARGIN AVG 3Y
14.44%
GROSS MARGIN AVG 5Y
19.21%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+22.40%
CURRENT VS 3Y AVG
+57.86%
CURRENT VS 5Y AVG
+18.62%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.73%
median of 629 covered companies
CURRENT VS SECTOR MEDIAN
-45.39%
vs the sector median at left
Market Cap
$5.85M
Gross Margin
-1.29%
TTM Avg
-3.77%
3Y Avg
16.02%
5Y Avg
20.70%
Market Cap
$5.93M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-2.09%
Market Cap
$5.70M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$6.01M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
83.33%
Market Cap
$5.54M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucyd, Inc (LUCY) | $5.85M | 22.79% | 18.62% | 14.44% | 19.21% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.85M | -1.29% | -3.77% | 16.02% | 20.70% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $5.93M | 0.00% | 0.00% | 0.00% | -2.09% |
| enVVeno Medical Corporation (NVNO)vs › | $5.70M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.01M | 100.00% | 100.00% | 100.00% | 83.33% |
| Femasys Inc. (FEMY)vs › | $6.07M | 61.96% | 64.25% | 64.10% | 65.91% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.54M | 0.00% | 0.00% | 0.00% | 0.00% |
| Biomerica, Inc. (BMRA)vs › | $6.21M | 8.09% | 8.76% | 9.29% | 9.67% |
| Alzamend Neuro Inc (ALZN)vs › | $5.36M | 0.00% | 0.00% | 0.00% | 0.00% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.27M | 48.63% | 44.74% | 40.32% | 43.55% |
Gross Margin
22.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 24.00% |
| 2026-03-31 | 22.68% |
| 2025-12-31 | 11.96% |
| 2025-09-30 | 36.65% |
| 2025-06-30 | -2.19% |
| 2025-03-31 | 48.52% |
| 2024-12-31 | 13.57% |
| 2024-09-30 | 23.40% |
| 2024-06-30 | 17.87% |
| 2024-03-31 | 1.81% |
| 2023-12-31 | -29.26% |
| 2023-09-30 | 36.21% |
| 2023-06-30 | -17.55% |
| 2023-03-31 | 7.10% |
| 2022-12-31 | -293.42% |
| 2022-09-30 | 15.05% |
| 2022-06-30 | 21.12% |
| 2022-03-31 | 31.52% |
| 2021-12-31 | 23.76% |
| 2021-09-30 | 23.86% |
| 2021-06-30 | 25.71% |
| 2021-03-31 | 7.97% |
| 2020-12-31 | -68.69% |
| 2020-09-30 | -11.24% |
| 2020-06-30 | 3.15% |
| 2020-03-31 | 3.17% |
